For people with liver cancer that can't be removed by surgery, who receive a treatment that cuts off the tumor's blood supply, adding vitamin K is linked to a much lower risk of the cancer worsening. The risk goes down by about half.
See the scientific wording
In patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization (TACE), adjunctive vitamin K is associated with a 49% reduction in the risk of disease progression (hazard ratio 0.51, 95% confidence interval 0.34–0.77), indicating a pronounced benefit in this subgroup.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
The study looked at many liver cancer patients and found that those receiving vitamin K along with TACE had slower cancer progression, with the exact same numbers mentioned in the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K2 helps slow down liver cancer by doing two important things. First, it stops the cancer cells from multiplying by turning off a growth signal and turning on a brake that makes the cells pause. Second, it blocks the formation of new blood vessels that the tumor needs to get food and oxygen. So the cancer can't grow as fast and is less likely to spread.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
For people with liver cancer that can't be removed by surgery, who receive a treatment that cuts off the tumor's blood supply, adding vitamin K is linked to a much lower risk of the cancer worsening. The risk goes down by about half.
Mechanism
1 studyVitamin K2 works in two ways to slow down liver cancer: it stops cancer cells from growing and dividing, and it prevents the tumor from forming new blood vessels to bring it food and oxygen. This makes it harder for the cancer to grow and spread.
Vitamin K2 helps slow down liver cancer by doing two important things. First, it stops the cancer cells from multiplying by turning off a growth signal and turning on a brake that makes the cells pause. Second, it blocks the formation of new blood vessels that the tumor needs to get food and oxygen. So the cancer can't grow as fast and is less likely to spread.
Transarterial chemoembolization (TACE) creates a shortage of oxygen and nutrients in the tumor area, which damages the tumor cells and triggers a stress response.
This stress response increases the production of hypoxia-inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor (VEGF), promoting the growth of new blood vessels to supply the tumor.
Vitamin K2 blocks the activation of a protein called nuclear factor kappa B (NF-κB) by inhibiting its upstream activator IKK kinase, which prevents the phosphorylation of IκB and the subsequent release of NF-κB.
Reduced NF-κB activity lowers the expression of cyclin D1, a protein that drives cell division, thereby slowing the proliferation of cancer cells.
Vitamin K2 also inhibits protein kinase C (PKC) and PKD1, which leads to activation of the p53 pathway and increased transcription of p21, causing cell cycle arrest.
Simultaneously, vitamin K2 selectively inhibits phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), blocking the downstream signaling that would otherwise trigger the formation of new blood vessels.
By directly inhibiting cancer cell proliferation through NF-κB and p53 pathways and preventing the post-TACE angiogenic rebound via VEGFR2 blockade, vitamin K2 slows tumor growth and reduces the risk of disease progression.
Evidence from Studies
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
The study looked at many liver cancer patients and found that those receiving vitamin K along with TACE had slower cancer progression, with the exact same numbers mentioned in the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials Evaluating Adjunctive Vitamin K for Unresectable Hepatocellular Carcinoma Undergoing TACE
Comprehensive search of databases for randomized controlled trials comparing TACE plus vitamin K to TACE alone or with placebo in patients with unresectable hepatocellular carcinoma, with outcome of disease progression (time to progression, progression-free survival) and meta-analysis of hazard ratios.
Randomized Controlled Trial of Vitamin K vs Placebo in Patients with Unresectable HCC Undergoing TACE
Prospective, double-blind, placebo-controlled randomized trial in patients with unresectable HCC scheduled for TACE, randomized to receive vitamin K or matching placebo for a specified duration (e.g., 12 months), with primary outcome of time to disease progression assessed by imaging.
Prospective Cohort Study Investigating the Association between Vitamin K Use and Disease Progression in Patients Undergoing TACE
Prospective cohort study following patients with unresectable HCC undergoing TACE, recording vitamin K supplementation (dose, duration), and tracking disease progression over a defined period (e.g., 2-3 years) with multivariable adjustment for confounders.
Case-Control Study Examining Historical Vitamin K Supplementation in HCC Patients with and without Disease Progression
Case-control study using medical records: identify cases of disease progression after TACE and matched controls without progression, then assess prior vitamin K supplementation history (e.g., dose, duration) through records or patient interviews.